[{"id":"5a84f8a3-f42b-4227-a0cd-33a7cd9fe530","acronym":"","url":"https://clinicaltrials.gov/study/NCT01713582","created_at":"2021-07-05T16:23:11.611Z","updated_at":"2024-07-02T16:36:35.612Z","phase":"Phase 1","brief_title":"A Dose-finding Study of the Bromodomain (Brd) Inhibitor OTX015/ Birabresib (MK-8628) in Hematologic Malignancies (MK-8628-001)","source_id_and_acronym":"NCT01713582","lead_sponsor":"Oncoethix GmbH","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e birabresib (OTX015)"],"overall_status":"Completed","enrollment":" Enrollment 141","initiation":"Initiation: 12/14/2012","start_date":" 12/14/2012","primary_txt":" Primary completion: 01/20/2017","primary_completion_date":" 01/20/2017","study_txt":" Completion: 01/20/2017","study_completion_date":" 01/20/2017","last_update_posted":"2021-01-26"},{"id":"a79a3ada-bd2e-4436-944e-2fbb8127fac0","acronym":"","url":"https://clinicaltrials.gov/study/NCT02259114","created_at":"2021-01-18T10:36:46.682Z","updated_at":"2024-07-02T16:36:35.600Z","phase":"Phase 1","brief_title":"A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003)","source_id_and_acronym":"NCT02259114","lead_sponsor":"Oncoethix GmbH","biomarkers":" KRAS • ALK • NUTM1","pipe":" | ","alterations":" KRAS mutation • ALK rearrangement • ALK fusion","tags":["KRAS • ALK • NUTM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • ALK rearrangement • ALK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e birabresib (OTX015)"],"overall_status":"Completed","enrollment":" Enrollment 47","initiation":"Initiation: 10/23/2014","start_date":" 10/23/2014","primary_txt":" Primary completion: 03/03/2017","primary_completion_date":" 03/03/2017","study_txt":" Completion: 03/03/2017","study_completion_date":" 03/03/2017","last_update_posted":"2021-01-26"}]